Introduction: To compare the efficacy and safety between tadalafil once-a-day and tadalafil on-demand dosing regimen in patients with ED. Materials and Methods: A systematic search of Medline, Embase, and Cochrane Library was performed to identify all randomized controlled trials (RCTs) that compared tadalafil used a once-a-day with an on-demand dosing regimen for erectile dysfunction. A secondary hand-search was performed in relevant journals, references, and the grey literature. Meta-analyses were performed using Review Manager version 5.3.0. Results: Six RCTs involving a total of 1,534 patients were included in this review. All studies reported the International Index of Erectile Function-Erectile Function domain score and the results of the meta-analysis showed no difference between the groups. The overall pooled estimated weighted mean differences (WMD) was 0.97 (95% CI -0.37 to 2.32; p = 0.16). Meta-analyses of Sexual Encounter Profile questions 2 and 3 (SEP-2 and SEP-3) showed that the once-a-day dosing regimen was superior to the on-demand regimen with statistical significance. The WMD of SEP-2 and SEP-3 were 10.32 (95% CI 3.16-17.48; p = 0.005) and 11.07 (95% CI 2.57-19.56; p = 0.01), respectively. Both dosing regimens of tadalafil showed similar complication rates. The meta-analyses of adverse events showed no significant differences. Conclusions: The efficacy rates of tadalafil once-a-day and on-demand were similar. No significant difference in safety was found between the 2 dose regimens of tadalafil.

Keywords:
Dosing regimen, Erectile dysfunction, Systematic review, Tadalafil
1.
NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.
2.
Kubin M, Wagner G, Fugl-Meyer AR: Epidemiology of erectile dysfunction. Int J Impot Res 2003;15:63-71.
3.
Gratzke C, Angulo J, Chitaley K, Dai YT, Kim NN, et al: Anatomy, physiology, and pathophysiology of erectile dysfunction. Curr Drug Targets 2015;16:411-419.
4.
Saleh A, Abboudi H, Ghazal-Aswad M, Mayer EK, Vale JA: Management of erectile dysfunction post-radical prostatectomy. Res Rep Urol 2015;7:19-33.
5.
Rosen RC, Kostis JB: Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003;92:9-18.
6.
Huang SA, Lie JD: Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. P T 2013;38:407-419.
7.
Choi H, Kim JH, Shim JS, Park JY, Kang SH, et al: Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms. Int J Impot Res 2015;27:33-37.
8.
Porst H, Gacci M, Büttner H, Henneges C, Boess F: Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. Eur Urol 2014;65:455-464.
9.
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, et al: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
10.
Buvat J, Büttner H, Hatzimouratidis K, Vendeira PA, Moncada I, et al: Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. J Sex Med 2013;10:1592-1602.
11.
Kang DH, Lee JY, Chung JH, Cho JM, Lee SH, et al: Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction. Int J Clin Pract 2012;66:813-820.
12.
McMahon C: Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005;2:415-425; discussion 425-427.
13.
Rubio-Aurioles E, Porst H, Kim ED, Montorsi F, Hackett G, et al: A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med 2012;9:1418-1429.
14.
Montorsi F, Brock G, Stolzenburg JU, Mulhall J, Moncada I, et al: Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). Eur Urol 2014;65:587-596.
15.
Ricardi U, Gontero P, Ciammella P, Badellino S, Valentino F, et al: Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial. J Sex Med 2010;7:2851-2859.
16.
Wang R, Burnett AL, Heller WH, Omori K, Kotera J, et al: Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med 2012;9:2122-2129.
17.
Wrishko R, Sorsaburu S, Wong D, Strawbridge A, McGill J: Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. J Sex Med 2009;6:2039-2048.
18.
Hatzimouratidis K, Buvat J, Büttner H, Vendeira PA, Moncada I, et al: Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study. Int J Impot Res 2014;26:223-229.
19.
Kim ED, Seftel AD, Goldfischer ER, Ni X, Burns PR: A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy. J Sex Med 2014;11:820-830.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.